Denali Therapeutics (DNLI) Upgraded to Strong-Buy at ValuEngine

Denali Therapeutics (NASDAQ:DNLI) was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday, March 30th, ValuEngine reports.

A number of other research firms have also recently issued reports on DNLI. Cantor Fitzgerald cut shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating and set a $25.00 price target for the company. in a report on Tuesday, January 29th. Zacks Investment Research upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a report on Thursday, January 3rd.

NASDAQ:DNLI traded down $1.03 during trading hours on Friday, hitting $25.17. 481,126 shares of the stock traded hands, compared to its average volume of 435,327. Denali Therapeutics has a fifty-two week low of $12.32 and a fifty-two week high of $28.86. The company has a market cap of $2.40 billion, a P/E ratio of -64.54 and a beta of 2.11.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Tuesday, March 12th. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.90. The business had revenue of $125.68 million for the quarter, compared to the consensus estimate of $9.73 million. Denali Therapeutics had a negative net margin of 28.06% and a negative return on equity of 7.12%. Analysts expect that Denali Therapeutics will post -1.69 EPS for the current year.

In related news, COO Alexander O. Schuth sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $28.05, for a total value of $210,375.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ryan J. Watts sold 18,334 shares of the firm’s stock in a transaction that occurred on Tuesday, February 5th. The shares were sold at an average price of $18.72, for a total transaction of $343,212.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 78,500 shares of company stock valued at $1,756,548. Corporate insiders own 21.30% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Baillie Gifford & Co. boosted its stake in Denali Therapeutics by 13.5% in the fourth quarter. Baillie Gifford & Co. now owns 6,227,724 shares of the company’s stock valued at $128,665,000 after acquiring an additional 741,303 shares during the last quarter. Vanguard Group Inc boosted its position in shares of Denali Therapeutics by 52.5% during the third quarter. Vanguard Group Inc now owns 4,827,710 shares of the company’s stock worth $104,954,000 after purchasing an additional 1,660,984 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Denali Therapeutics by 52.5% during the third quarter. Vanguard Group Inc. now owns 4,827,710 shares of the company’s stock worth $104,954,000 after purchasing an additional 1,660,984 shares in the last quarter. BlackRock Inc. boosted its position in shares of Denali Therapeutics by 38.3% during the fourth quarter. BlackRock Inc. now owns 4,572,695 shares of the company’s stock worth $94,469,000 after purchasing an additional 1,265,645 shares in the last quarter. Finally, Lord Abbett & CO. LLC boosted its position in shares of Denali Therapeutics by 27.8% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,438,608 shares of the company’s stock worth $29,722,000 after purchasing an additional 313,153 shares in the last quarter. 71.47% of the stock is currently owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

See Also: Yield Curve

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.